Fennec Pharmaceuticals Inc. (FENC)
NASDAQ: FENC · Real-Time Price · USD
11.62
+0.72 (6.61%)
Nov 13, 2026, 4:00 PM EST - Market closed
Fennec Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 48.68 | 36.79 | 26.63 | 13.27 | 23.77 | 21.1 |
Cash & Short-Term Investments | 48.68 | 36.79 | 26.63 | 13.27 | 23.77 | 21.1 |
Cash Growth | 121.83% | 38.12% | 100.72% | -44.19% | 12.67% | -30.46% |
Receivables | 23.79 | 23.22 | 12.88 | 8.81 | 1.55 | - |
Inventory | 2.12 | 1.57 | 1.06 | 2.16 | 0.58 | - |
Prepaid Expenses | 4.95 | 3.74 | 3.08 | 2.58 | 0.77 | 1.03 |
Other Current Assets | 1.42 | 1.73 | 0.47 | 0.04 | 0.06 | 0.25 |
Total Current Assets | 80.95 | 67.04 | 44.12 | 26.86 | 26.73 | 22.39 |
Long-Term Accounts Receivable | 1.95 | 2.79 | - | - | - | - |
Long-Term Deferred Charges | 0.64 | 0.72 | 0.82 | 0.01 | 0.21 | 0.03 |
Total Assets | 83.54 | 70.55 | 44.95 | 26.86 | 26.94 | 22.41 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 4.61 | 4.64 | 3.24 | 3.78 | 2.39 | 0.78 |
Accrued Expenses | 5.83 | 5.64 | 3.43 | 3.75 | 2.22 | 0.88 |
Current Portion of Leases | - | - | 0 | 0.02 | - | - |
Current Unearned Revenue | 2.81 | 0.25 | 0.25 | - | - | - |
Total Current Liabilities | 13.24 | 10.52 | 6.92 | 7.55 | 4.61 | 1.65 |
Long-Term Debt | - | - | 19.34 | 30.93 | 24.9 | 4.99 |
Long-Term Unearned Revenue | 21.11 | 24.56 | 24.56 | 0 | - | - |
Total Liabilities | 34.35 | 35.08 | 50.82 | 38.49 | 29.51 | 6.64 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 194.09 | 189.91 | 145.61 | 144.31 | 142.59 | 140.8 |
Additional Paid-In Capital | 76.46 | 73.75 | 66.96 | 62.07 | 56.8 | 53.21 |
Retained Earnings | -222.61 | -229.42 | -219.68 | -219.25 | -203.2 | -179.49 |
Comprehensive Income & Other | 1.24 | 1.24 | 1.24 | 1.24 | 1.24 | 1.24 |
Shareholders' Equity | 49.19 | 35.47 | -5.87 | -11.62 | -2.57 | 15.77 |
Total Liabilities & Equity | 83.54 | 70.55 | 44.95 | 26.86 | 26.94 | 22.41 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | - | - | 19.34 | 30.95 | 24.9 | 4.99 |
Net Cash (Debt) | 48.68 | 36.79 | 7.29 | -17.68 | -1.13 | 16.11 |
Net Cash Growth | 1794.32% | 404.36% | - | - | - | -46.90% |
Net Cash Per Share | 1.38 | 1.29 | 0.27 | -0.67 | -0.04 | 0.62 |
Filing Date Shares Outstanding | 35.31 | 34.48 | 27.59 | 27.1 | 26.41 | 26.01 |
Total Common Shares Outstanding | 35.22 | 34.16 | 27.53 | 27.03 | 26.36 | 26.01 |
Working Capital | 67.71 | 56.53 | 37.21 | 19.31 | 22.12 | 20.73 |
Book Value Per Share | 1.40 | 1.04 | -0.21 | -0.43 | -0.10 | 0.61 |
Tangible Book Value | 49.19 | 35.47 | -5.87 | -11.62 | -2.57 | 15.77 |
Tangible Book Value Per Share | 1.40 | 1.04 | -0.21 | -0.43 | -0.10 | 0.61 |